Abstract

Development of submodels of organs within physiologically-based pharmacokinetic (PBPK) principles and beyond simple perfusion limitations may be challenging because of underdeveloped in vitro-in vivo extrapolation approaches or lack of suitable clinical data for model refinement. However, advantage of such models in predicting clinical observations in divergent patient groups is now commonly acknowledged. Mechanistic understanding of altered renal secretion in renal impairment is one area that may benefit from such models, despite knowledge gaps in renal pathophysiology. In the current study, a PBPK kidney model was developed for digoxin, accounting for the roles of organic anion transporting peptide 4C1 (OATP4C1) and P-glycoprotein (P-gp) in its tubular secretion, with the aim to investigate the impact of age and renal impairment (moderate to severe) on renal drug disposition. Initial PBPK simulations based on changes in glomerular filtration rate (GFR) underestimated the observed reduction in digoxin renal excretion clearance (CLR) in subjects with moderately impaired renal function relative to healthy. Reduction in either proximal tubule cell number or the OATP4C1 abundance in the mechanistic kidney model successfully predicted 59% decrease in digoxin CLR, in particular when these changes were proportional to reduction in GFR. In contrast, predicted proximal tubule concentration of digoxin was only sensitive to changes in the transporter expression/ million proximal tubule cells. Based on the mechanistic modeling, reduced proximal tubule cellularity and OATP4C1 abundance, and inhibition of OATP4C1-mediated transport, are proposed as possible causes of reduced digoxin renal secretion in renally impaired patients.

Highlights

  • Dosage adjustment is often required in patients with impaired renal function because of the impact this condition may have in altered drug clearance through either decreased renal excretion alone or in combination with reduced metabolism

  • A physiologicallybased pharmacokinetic (PBPK) kidney model was developed for digoxin, accounting for the roles of organic anion transporting peptide 4C1 (OATP4C1) and P-glycoprotein (P-gp) in its tubular secretion, with the aim to investigate the impact of age and renal impairment on renal drug disposition

  • Simulated AUC0-‘ was 29% and 39% higher compared with setting when mechanistic kidney model (MechKiM) was not activated (i.e., CLR defined using single input parameter) for the "filtration only" and "filtration and reabsorption" scenarios, respectively

Read more

Summary

Introduction

Dosage adjustment is often required in patients with impaired renal function because of the impact this condition may have in altered drug clearance through either decreased renal excretion alone or in combination with reduced metabolism. Such decisions on dosage adjustment will be supported by recommendations on drug labels that are currently based on statistical analyses of clinical data, often from dedicated but small sized studies (US Food Drug Admin, 2010; Matzke et al, 2011; European Medicines Agency, 2014). Despite recent efforts, evidence for the applicability of PBPK for the prediction of transporter-mediated disposition remains less comprehensive, for the kidney

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call